FierceBiotech 24 feb 2026 Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
FierceBiotech 24 feb 2026 Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months
FierceBiotech 24 feb 2026 ‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
FierceBiotech 23 feb 2026 UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
FierceBiotech 23 feb 2026 iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
FierceBiotech 20 feb 2026 Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint